Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences
Alternative Names: Cobicistat/elvitegravir/emtricitabine/TAF; Cobicistat/emtricitabine/elvitegravir/tenofovir-alafenamide; E/C/F/TAF; Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Elvitegravir/emtricitabine/tenofovir-alafenamide/cobicistat; Emtricitabine/cobicistat/elvitegravir/tenofovir alafenamide; Emtricitabine/tenofovir-alafenamide/cobicistat/elvitegravir; Genvoya; Tenofovir alafenamide/cobicistat/elvitegravir/emtricitabine; Tenofovir-alafenamide/elvitegravir/emtricitabine/cobicistatLatest Information Update: 29 Nov 2022
At a glance
- Originator Gilead Sciences
- Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Quinolones; Small molecules
- Mechanism of Action Cytochrome P-450 enzyme system inhibitors; HIV integrase inhibitors; Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 29 Nov 2022 No development reported - Phase-III for HIV-1 infections (In the elderly, Treatment-experienced) in United Kingdom, Italy, France (PO)
- 25 Nov 2022 Gilead Sciences completes a phase III trial in HIV infection (NCT02660905)
- 07 Nov 2022 Efficacy data from the trial was presented at the American College of Clinical Pharmacology Annual Meeting (ACCP-2022)